Absci (ABSI) vs ADMA Biologics (ADMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Absci (ABSI) has outperformed ADMA Biologics (ADMA) over the past year, gaining 153.4% versus a loss of 29.7%. Over five years, ADMA leads with a +841.8% price change compared with -4.4% for ABSI. ADMA Biologics is the larger company by market cap ($2.32 billion vs $1.74 billion), about 1.3 times the size.
ADMA Biologics converts more of its revenue into profit, with a net margin of 28.8% versus -4113.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABSI | ADMA |
|---|---|---|
| Share price | $10.16 | $10.36 |
| Market cap | $1.74B | $2.32B |
| 1-day change | +13.65% | +0.29% |
| YTD return | +191.12% | -43.20% |
| 1-year return | +153.37% | -29.72% |
| 5-year return | -4.42% | +841.82% |
| P/E ratio (TTM) | — | 14.80 |
| Forward P/E | — | 10.98 |
| EPS (TTM) | $-0.79 | $0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.80M | $510.17M |
| Revenue growth (YoY) | -38.24% | +19.63% |
| Net income (latest FY) | $-115.18M | $146.93M |
| Gross margin | — | 57.39% |
| Operating margin | -4297.04% | 37.53% |
| Net margin | -4113.68% | 28.80% |
| 52-week high | $12.06 | $20.46 |
| 52-week low | $2.24 | $7.21 |
| Distance from 52-week high | -15.72% | -49.36% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +41.73% | +64.09% |
| Average volume | 3.43M | 2.66M |
| Shares outstanding | 171.61M | 223.98M |
| Employees | 140 | 640 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABSI has outperformed ADMA by 183.1 percentage points over the past year.
- ADMA Biologics is more profitable, keeping 28.8 cents of every revenue dollar as net income versus -4113.7 cents for Absci.
- ADMA Biologics grew revenue faster in its latest fiscal year (+19.63% vs -38.24%).
About Absci
ABSI stock →Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Healthcare · Biotechnology · 140 employees
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Healthcare · Biotechnology · 640 employees
ABSI vs ADMA FAQ
Which is bigger, Absci or ADMA Biologics?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.32B compared with $1.74B for Absci (ABSI).
Which stock has performed better over the past year, ABSI or ADMA?
ABSI returned +153.37% over the past 12 months, compared with -29.72% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are Absci and ADMA Biologics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.